KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study.

Vera Bril, Carlo Antozzi, Tomasz Berkowicz, Artur Drużdż, Rachana K Gandhi Mehta, Zabeen K Mahuwala, Jana Zschüntzsch, Marion Boehnlein, Virginie Kerbusch, Andreea Lavrov, Mark Morris, Puneet Singh, M Isabel Leite

J Neurol 272(10) 686

PMID41074934
PMCIDPMC12515207
DOI10.1007/s00415-025-13420-6
发表日期2025-10-11
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:AI 判定为 other;Fig. 5:非 KM 图;另有 1 张未列出。
摘要

摘要

BACKGROUND: The phase 3, open-label, randomised, crossover MG0020 study investigated rozanolixizumab self-administration, efficacy, and safety in patients with generalised myasthenia gravis (gMG) using infusion pump and manual push methods. METHODS: Adults with gMG received once-weekly rozanolixizumab for 18 weeks, comprising a 6-week Training Period and two 6-week Self-Administration Periods where patients were randomised 1:1 to Sequence 1 (infusion pump then manual push) or Sequence 2 (manual push then infusion pump). The primary endpoint was successful rozanolixizumab self-administration (choosing correct infusion site, administering subcutaneously, delivering intended dose), evaluated by a healthcare professional (HCP) at weeks 12 and 18. Secondary endpoints included treatment-emergent adverse events (TEAEs). Additional endpoints included change from baseline in total immunoglobulin G (IgG) and Myasthenia Gravis Activities of Daily Living (MG-ADL) score, and patients' administration method preference. RESULTS: Sixty-two patients received treatment; 55 were randomised (Sequence 1: n = 28; Sequence 2: n = 27). The self-administration success rate was 100% with both methods. Decreases from baseline in IgG and MG-ADL score were maintained during self-administration with both methods. TEAEs occurred in 47/62 (75.8%) patients; most events (161/165 [97.6%]) were mild or moderate. Incidence was comparable for both methods. Most patients (35/55 [63.6%]) preferred self-administration to HCP administration (5/55 [9.1%]); more preferred manual push (25/55 [45.5%]) to infusion pump (17/55 [30.9%]). CONCLUSIONS: All patients successfully self-administered rozanolixizumab; more patients preferred manual push. Efficacy and safety were consistent with the known HCP-administered profile. These results support rozanolixizumab self-administration and manual push administration in patients with gMG. TRIAL REGISTRATION: NCT05681715 (registered 4 January 2023).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study design. a Patients completing all treatment periods, including the End of Treatment Visit, and moving on to either a post-study access programme or commercially available rozanolixizumab during the Safety Follow-Up Period underwent an earlier End of Study Visit prior to this move. HCP, healthcare professional; R, randomisation.
非 KM Figure
Fig. 2Patient study disposition. AE, adverse event; IP, infusion pump; MP, manual push; RSS, randomised safety set; SA, self-administration; SS, safety set
非 KM Figure
Fig. 3Self-administration success rate by study sequence. Full analysis set. Successful self-administration was assessed at week 12 (visit 13) for Self-Administration Period 1 and week 18 (visit 19) for Self-Administration Period 2. Percentages are based on the number of patients with non-missing data. Patients are grouped according to the self-administration method within the study period. RLZ, rozanolixizumab
非 KM Figure
Fig. 4Median percentage change from baseline in total IgG. Randomised safety set. IgG values up to and including 8 weeks after the start date of rescue therapy were excluded. Median baseline value was 9.87 for Sequence 1 ( N = 28) and 9.37 for Sequence 2 ( N = 27). a Baseline values were defined as the last available measurement before the first administration of study drug at week 1. CFB, change from baseline; HCP, healthcare professional; IgG, immunoglobulin G; IP, infusion pump; MP, manual push; R, randomisation
非 KM Figure
Fig. 5Mean change from baseline in MG-ADL score. Randomised safety set. Mean (SD) baseline value was 7.07 (3.89) for Sequence 1 ( N = 28) and 7.52 (3.94) for Sequence 2 ( N = 27). a Baseline values were defined as the last available measurement before the first administration of study drug at week 1. CFB, change from baseline; HCP, healthcare professional; IP, infusion pump; MG-ADL, Myasthenia Gravis Activities of Daily Living; MP, manual push; R, randomisation; SD, standard deviation
非 KM Figure
Fig. 6Patient preference for ( a ) HCP-administered versus self-administered rozanolixizumab and ( b ) manual push versus infusion pump self-administration . Randomised safety set. Questionnaire was administered at the last self-administration visit and answers were based on patients’ overall self-administration experience. Percentages are based on the number of patients with an assessment at week 18. Self-administration includes study drug administration by patient or caregiver. HCP, healthcare professional; IP, infusion pump, MP, manual push; RLZ, rozanolixizumab
非 KM Figure